AGXT2 and coronary artery disorder: This suggests that despite upregulation of AGXT2 resulting in increased DMGV production through the degradation of ADMA, a potent inhibitor of endothelial nitric oxide production, the association of DMGV with CAD is not dependent on ADMA [16,46].